266 related articles for article (PubMed ID: 8635362)
1. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
[TBL] [Abstract][Full Text] [Related]
2. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation.
Ross DJ; Lewis MI; Kramer M; Vo A; Kass RM
Chest; 1997 Nov; 112(5):1175-9. PubMed ID: 9367453
[TBL] [Abstract][Full Text] [Related]
3. Induction immunosuppression for lung transplantation with OKT3.
Wain JC; Wright CD; Ryan DP; Zorb SL; Mathisen DJ; Ginns LC
Ann Thorac Surg; 1999 Jan; 67(1):187-93. PubMed ID: 10086547
[TBL] [Abstract][Full Text] [Related]
4. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis.
Barlow CW; Moon MR; Green GR; Gamberg P; Theodore J; Reitz BA; Robbins RC
Transpl Int; 2001 Aug; 14(4):234-9. PubMed ID: 11512056
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
[TBL] [Abstract][Full Text] [Related]
7. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.
Kroshus TJ; Kshettry VR; Savik K; John R; Hertz MI; Bolman RM
J Thorac Cardiovasc Surg; 1997 Aug; 114(2):195-202. PubMed ID: 9270635
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience.
Ross DJ; Waters PF; Levine M; Kramer M; Ruzevich S; Kass RM
J Heart Lung Transplant; 1998 Aug; 17(8):768-74. PubMed ID: 9730425
[TBL] [Abstract][Full Text] [Related]
10. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
11. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
12. The impact of cytolytic therapy on bronchiolitis obliterans syndrome.
Date H; Lynch JP; Sundaresan S; Patterson GA; Trulock EP
J Heart Lung Transplant; 1998 Sep; 17(9):869-75. PubMed ID: 9773858
[TBL] [Abstract][Full Text] [Related]
13. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
[TBL] [Abstract][Full Text] [Related]
15. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
16. "Refractoriness" of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts.
Ross DJ; Marchevsky A; Kramer M; Kass RM
J Heart Lung Transplant; 1997 Aug; 16(8):832-8. PubMed ID: 9286775
[TBL] [Abstract][Full Text] [Related]
17. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation.
McVicar JP; Kowdley KV; Emond MJ; Barr D; Marsh CL; Carithers RL; Perkins JD
Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724
[TBL] [Abstract][Full Text] [Related]
18. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
19. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
